



[Print this Page for Your Records](#)

[Close Window](#)

Control/Tracking Number: 2017-A-6194-Diabetes

Activity: Abstract

Current Date/Time: 1/3/2017 3:01:15 PM

Evidence Map of Glimepiride: Results of a Bibliometric Analysis for India, China and the World during 1988-2016

Author Block: BENSLEY GONSALVES, RAJESH YADAV, NAVNEET WADHWA, *Mumbai, India*

Abstract:

Glimepiride is a well-established anti-diabetic agent with substantial weight for the evidence based medicine since the first publication in 1988. We explore the continuum of published strength of evidences for glimepiride through a comparative analytical approach across the publications from the World, China, and India. We searched pubmed and Cochrane medical library electronic databases since inception to December 2016. The rate of articles published per million population with diabetes across the world was calculated and compared as a benchmark for India and China to develop an index score of publications. PubMed cited 1117 articles for glimepiride with 744 human studies. Two thirds (750) of the publications are indexed in the last one decade of which 60% (443) have been published in last five years. India accounts for approximately 16.8% population of diabetics and contributes 8% of publications, compared to 6% contribution from China for publications on glimepiride. The indexed score from India and China was benchmarked against the global score for the parameters including the human studies, clinical trials, randomised clinical trials, reviews, meta-analysis and case reports with the publication time lines for last 5 years and 10 years. (Table) India scores over China in several parameters with a scope to escalate the quantum with the

Table : Comparative Index Score of Publications for Glimepiride across the World, India and China

Absolute No (Index score)	No. of Diabetes population (million) 2015	Overall	Human Studies	CT	RCTs	Review	Meta Analysis	Case Reports	5 Years	10 Years
World (100)	415	1117	744	292	39	166	14	51	443	750
India (Index Score)	70 (0.16)	95 (0.08)	32 (0.04)	10 (0.03)	8 (0.2)	5 (0.03)	0	3 (0.05)	55 (0.12)	86 (0.11)
China (Index Score)	114 (0.27)	71 (0.06)	39 (0.05)	13 (0.04)	12 (0.3)	3 (0.01)	3 (0.21)	1 (0.01)	49 (0.11)	64 (0.08)

higher level of evidences for glimepiride
:

Author Disclosure Information:

B. Gonsalves: None. **R. Yadav:** None. **N. Wadhwa:** None.

Category (Complete): 12-E Clinical Therapeutics/New Technology–Oral Agents

Presentation Preference (Complete): Oral Preferred

Financial Support (Complete):

* **ADA Support:** No

Keyword (Complete): Sulfonylureas ; Meta-analysis

Payment (Complete): Your credit card order has been processed on Tuesday 3 January 2017 at 3:00 PM.

Status: Complete

[American Diabetes Association](#)

2451 Crystal Drive, Suite 900

Arlington, VA 22202

Questions about abstracts?

Contact the ADA at

abstracts@diabetes.org

For Technical Support please contact [cOASIS Helpdesk](#) at

oasis@support.ctimeetingtech.com or 217-398-1792

between the hours of 7:00 a.m. and 6:00 p.m. (CST) Monday through Friday.

Tech Support Holiday Hours: December 23rd and 30th open from 7:00am-1:30pm (CST), CLOSED December 26th and January 2nd.

[Leave OASIS Feedback](#)

Powered by [cOASIS](#), The Online Abstract Submission and Invitation System SM

© 1996 - 2017 [CTI Meeting Technology](#) All rights reserved.